At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 143 enrolled
Drug / intervention
Fulvestrant +1 moredrug
Likely dose
Fulvestrant 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
In Brief
A Phase 2 clinical trial evaluating Fulvestrant for Advanced Breast Cancer and Metastatic Breast Cancer. Completed, enrolled 143 participants across 35 sites.
Detailed Summary
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer, Metastatic Breast Cancer
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedMar 2006
Primary CompletionMar 2008
Study CompletionFeb 2012
TodayJul 2026
First PostedMar 22, 2006
Enrollment StartMar 1, 2006
Primary CompletionMar 1, 2008
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.3 years ago
Interventions
Fulvestrantdrug
250 intramuscular injection
Fulvestrantdrug
500 mg intramuscular injection